Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | June 03, 2021 | June 07, 2021 |
| Damora Therapeutics, Inc.DMRA · Entity 4602 | Director | August 12, 2026 | August 13, 2026 |
| TCGX Acquisition Corp.TCGX · Entity 6504 | Director | August 04, 2026 | August 04, 2026 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date June 03, 2021 · Filed June 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2031-06-03 | Direct | 22,000 |
Reported balance
After 2021-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-03 · Grant · Acquired 22,000 · Balance 22,000 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2: The options are fully vested and exercisable as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant.
F2: The options are fully vested and exercisable as of the date of the grant.
Damora Therapeutics, Inc.
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.00 · Expires 2036-08-12 | Direct | 30,350 |
Reported balance
After 2026-08-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 30,350 · Balance 30,350 F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
TCGX Acquisition Corp.
Report date August 04, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 09, 2025 · Filed December 09, 2025
Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 277,075 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 159,762 · Balance 0 F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 3,421 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 5,032 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-09 · Disposition to issuer · Disposed 2,328 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-09 · Disposition to issuer · Disposed 4,739 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-09 · Disposition to issuer · Disposed 3,527 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-12-09 · Disposition to issuer · Disposed 292,179 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-12-09 · Disposition to issuer · Disposed 374,985 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-09 · Disposition to issuer · Disposed 233,252 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-12-09 · Disposition to issuer · Disposed 23,809 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-12-09 · Disposition to issuer · Disposed 165,289 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2025-12-09 · Disposition to issuer · Disposed 87,220 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2025-12-09 · Disposition to issuer · Disposed 238,973 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.09 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-12-09 · Disposition to issuer · Disposed 234,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2025-12-09 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").
F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2023 Filed May 3, 2023 20:28 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 25,000 | $0.62 | $15,375.00 |
DisclosureSEC source: 0000899243-23-012167 · doc4.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 434,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. Read SEC document |
| April 18, 2023 Filed May 3, 2023 20:28 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-23-012167 · doc4.xml · derivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,212 Underlying: Common Stock · 40,000 shares Expires 2028-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| April 18, 2023 Filed May 3, 2023 20:28 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 40,000 | $0.62 | $24,600.00 |
DisclosureSEC source: 0000899243-23-012167 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 16:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-23-010760 · doc4.xml · derivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,868 Underlying: Common Stock · 25,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F4 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 16:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 1,708 | $38.83 | $66,314.64 |
DisclosureSEC source: 0000899243-23-010760 · doc4.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 369,293 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.46 to $39.12, inclusive. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 16:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 23,292 | $37.88 | $882,261.36 |
DisclosureSEC source: 0000899243-23-010760 · doc4.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 371,001 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.45 to $38.41, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 16:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 25,000 | $0.62 | $15,375.00 |
DisclosureSEC source: 0000899243-23-010760 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 394,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:18 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Tax withholdingCommon Stock | 1,706 | $43.47 | $74,159.82 |
DisclosureSEC source: 0000899243-23-008399 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,293 F1 · kind: Represents shares required to be sold to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:21 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-23-006973 · doc4.xml · derivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,868 Underlying: Common Stock · 25,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F5 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:21 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 6,700 | $47.17 | $316,033.64 |
DisclosureSEC source: 0000899243-23-006973 · doc4.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,999 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.90 to $47.45, inclusive. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:21 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 16,035 | $46.60 | $747,154.03 |
DisclosureSEC source: 0000899243-23-006973 · doc4.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,699 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.90 to $46.89, inclusive. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:21 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 2,265 | $45.54 | $103,150.82 |
DisclosureSEC source: 0000899243-23-006973 · doc4.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,734 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.90 to $45.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:21 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 25,000 | $0.62 | $15,375.00 |
DisclosureSEC source: 0000899243-23-006973 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:25 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-23-003896 · doc4.xml · derivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,868 Underlying: Common Stock · 25,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, previously adopted by the reporting person. F5 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:25 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 2,000 | $50.14 | $100,284.00 |
DisclosureSEC source: 0000899243-23-003896 · doc4.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,999 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.06 to $50.31, inclusive. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:25 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 8,155 | $49.67 | $405,053.96 |
DisclosureSEC source: 0000899243-23-003896 · doc4.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,999 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.045 to $50.04, inclusive. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:25 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 14,845 | $48.57 | $721,057.28 |
DisclosureSEC source: 0000899243-23-003896 · doc4.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,154 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.03 to $49.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:25 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 25,000 | $0.62 | $15,375.00 |
DisclosureSEC source: 0000899243-23-003896 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, previously adopted by the reporting person. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-23-001053 · doc4.xml · derivative · entry 8 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,868 Underlying: Common Stock · 25,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F8 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 300 | $54.81 | $16,442.01 |
DisclosureSEC source: 0000899243-23-001053 · doc4.xml · nonDerivative · entry 7 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,999 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.80 to $54.81, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 3,900 | $54.37 | $212,046.90 |
DisclosureSEC source: 0000899243-23-001053 · doc4.xml · nonDerivative · entry 6 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,299 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.74 to $54.61, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 800 | $53.09 | $42,470.24 |
DisclosureSEC source: 0000899243-23-001053 · doc4.xml · nonDerivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,199 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $52.57 to $53.37, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 3,000 | $52.03 | $156,095.70 |
DisclosureSEC source: 0000899243-23-001053 · doc4.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,999 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $51.55 to $52.50, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 3,800 | $50.82 | $193,113.72 |
DisclosureSEC source: 0000899243-23-001053 · doc4.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,999 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.53 to $51.38, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 13,200 | $50.12 | $661,582.68 |
DisclosureSEC source: 0000899243-23-001053 · doc4.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,799 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.52 to $50.51, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 25,000 | $0.62 | $15,375.00 |
DisclosureSEC source: 0000899243-23-001053 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 19:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-22-039137 · doc4.xml · derivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,212 Underlying: Common Stock · 8,500 shares Expires 2028-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 19:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 87,220 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000899243-22-039137 · doc4.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,662 Underlying: Common Stock · 87,220 shares Expires 2031-12-07 F1 · date: On December 8, 2021, the Reporting Person was granted an option to purchase 261,662 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On December 16, 2022, the third performance milestone was achieved, resulting in the vesting of 87,220 shares underlying such option. F1 · derivative.exercise_date: On December 8, 2021, the Reporting Person was granted an option to purchase 261,662 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On December 16, 2022, the third performance milestone was achieved, resulting in the vesting of 87,220 shares underlying such option. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 19:46 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 8,500 | $0.62 | $5,227.50 |
DisclosureSEC source: 0000899243-22-039137 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 20:30 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 235,580 | $0.00 Strike: $42.95 | $0.00 |
DisclosureSEC source: 0000899243-22-038395 · doc4.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,580 Underlying: Common Stock · 235,580 shares Expires 2032-12-08 F2 · derivative.exercise_date: This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 20:30 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantCommon Stock | 52,351 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-038395 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,499 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 17:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-22-037482 · doc4.xml · derivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,868 Underlying: Common Stock · 10,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F3 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 17:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 10,000 | $46.07 | $460,700.00 |
DisclosureSEC source: 0000899243-22-037482 · doc4.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,148 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.79 to $46.62, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 17:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 10,000 | $0.62 | $6,150.00 |
DisclosureSEC source: 0000899243-22-037482 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 21:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-22-034846 · doc4.xml · derivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,868 Underlying: Common Stock · 10,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F5 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 21:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 500 | $44.02 | $22,010.00 |
DisclosureSEC source: 0000899243-22-034846 · doc4.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,148 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.99 to $44.11, inclusive. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 21:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 8,900 | $43.47 | $386,883.00 |
DisclosureSEC source: 0000899243-22-034846 · doc4.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,648 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.98 to $43.96, inclusive. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 21:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 600 | $42.15 | $25,290.00 |
DisclosureSEC source: 0000899243-22-034846 · doc4.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,548 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.93 to $42.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 21:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 10,000 | $0.62 | $6,150.00 |
DisclosureSEC source: 0000899243-22-034846 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 08:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-22-032884 · doc4.xml · derivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,868 Underlying: Common Stock · 10,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F4 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 08:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 100 | $34.39 | $3,439.00 |
DisclosureSEC source: 0000899243-22-032884 · doc4.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,148 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 08:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 5,350 | $33.57 | $179,599.50 |
DisclosureSEC source: 0000899243-22-032884 · doc4.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,248 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.28 to $34.00, inclusive. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 08:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 4,550 | $32.80 | $149,240.00 |
DisclosureSEC source: 0000899243-22-032884 · doc4.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,598 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.28 to $33.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 08:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 10,000 | $0.62 | $6,150.00 |
DisclosureSEC source: 0000899243-22-032884 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. Read SEC document |
| September 13, 2022 Filed Sep 13, 2022 21:13 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 87,221 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0001104659-22-099797 · tm2225839-1_4seq1.xml · derivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,442 Underlying: Common Stock · 87,221 shares Expires 2031-12-07 F3 · date: On December 8, 2021, the Reporting Person was granted an option to purchase 261,662 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 13, 2022, the second performance milestone was achieved, resulting in the vesting of 87,221 shares underlying such option. F3 · derivative.exercise_date: On December 8, 2021, the Reporting Person was granted an option to purchase 261,662 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 13, 2022, the second performance milestone was achieved, resulting in the vesting of 87,221 shares underlying such option. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 19:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-22-031201 · doc4.xml · derivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,868 Underlying: Common Stock · 60,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of this option vested on October 1, 2019, and the remaining 75% of this option shall vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 19:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 43,204 | $27.69 | $1,196,318.76 |
DisclosureSEC source: 0000899243-22-031201 · doc4.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,148 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $28.00, inclusive. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 19:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 16,796 | $26.74 | $449,125.04 |
DisclosureSEC source: 0000899243-22-031201 · doc4.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,352 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.25 to $27.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 19:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 60,000 | $0.62 | $36,900.00 |
DisclosureSEC source: 0000899243-22-031201 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person. Read SEC document |
| September 09, 2022 Filed Sep 13, 2022 21:13 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 87,221 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0001104659-22-099797 · tm2225839-1_4seq1.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,221 Underlying: Common Stock · 87,221 shares Expires 2031-12-07 F2 · date: On December 8, 2021, the Reporting Person was granted an option to purchase 261,662 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 9, 2022, the first performance milestone was achieved, resulting in the vesting of 87,221 shares underlying such option. F2 · derivative.exercise_date: On December 8, 2021, the Reporting Person was granted an option to purchase 261,662 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 9, 2022, the first performance milestone was achieved, resulting in the vesting of 87,221 shares underlying such option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.